Further experimental studies to the association between the mutation in KRAS gene and FIP1L1–RARA fusion on the clinical phenotype and progression of APL are needed to identify more effective therapeutic targets for APL. This evidence concerns the gene KRAS and acute promyelocytic leukemia.